Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Vertex Pharmaceuticals Cystic Fibrosis Treatment Appears to Work in Study


Shares of the biotech company soared this year on hope for a combination treatment for the deadly disease. The key to interpreting Thursday's data presentation: No negative surprises.

MINYANVILLE ORIGINAL Vertex Pharmaceuticals' (NASDAQ:VRTX) combination therapy improved lung function in cystic fibrosis patients and appears to be safe, results of a company-sponsored study showed Thursday. The data support further study, moving the drugs closer to a possible approval.

"These study results are an exciting step for the cystic fibrosis community and we look forward to the start of this pivotal (study) program early next year," lead researcher Michael P. Boyle of the Johns Hopkins Adult Cystic Fibrosis Center says in a statement.

Researchers disclosed mid-stage study results for the Vertex treatment Kalydeco combined with an experimental drug, VX-809, Thursday. While there was widespread optimism for good data from the study, shares jumped up and down in morning trading. The key takeaway was there were no bad surprises. The data was presented at a conference of the Cystic Fibrosis Foundation in Orlando.

The stock rose 3% to $58.45 in midday trading Thursday. The shares climbed more than 76% this year, largely on hope for the combination therapy.

Vertex won US approval in January to sell Kalydeco to a narrow group of cystic fibrosis patients with a particular genetic defect. Winning a broader approval of a combination therapy for the life-threatening disease would be a far bigger market opportunity. About 70,000 people worldwide have cystic fibrosis, including 30,000 in the US.

Analysts have estimated Kalydeco may be a multi-billion-dollar drug if approved for a broader patient population.

ISI Group analyst Mark Schoenebaum says the next big test for the stock will be in the first quarter of 2013 when he expects additional data will be disclosed about Kalydeco used in combination with another experimental drug, VX-661. Those additional results should give an even stronger indication of Kalydeco's potential, he says. If efficacy is confirmed with additional data, expect the stock to continue to rally, the analyst says.

In May, shares of Vertex surged after the company disclosed positive results for its drug combination. (See Vertex Pharmaceuticals Soars on Cystic Fibrosis Drug Study.) The company, which boasts an almost $13 billion market cap, has other investment catalysts: It sells a hepatitis C drug, Incivek, and is working on next-generation treatments for the liver-wasting virus. The company is led by CEO Jeffrey Leiden, a former Abbott Laboratories (NYSE:ABT) executive.

Vertex hosts a webcast at 6:30 p.m. ET Thursday to discuss the cystic fibrosis study.

Twitter: @brettchase

Follow the markets all day every day with a FREE 14 day trial to Buzz & Banter. Over 30 professional traders share their ideas in real-time. Learn more.
< Previous
  • 1
Next >
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos